Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis

Abstract

Background Obstructive sleep apnea (OSA) is the most prevalent sleep-related breathing disorder which could impair someone's quality of life and is also associated with poor outcomes from many diseases. Currently, the evidence regarding the link between OSA and coronavirus disease 2019 (COVID-19) is still conflicting. This study aims to analyze the relationship between OSA and poor outcomes of COVID-19. Materials and Methods We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until December 10 th , 2020. All articles published on COVID-19 and OSA were retrieved. The quality of the study was assessed using the Newcastle Ottawa Scale (NOS) tool for observational studies. Statistical analysis was done using Review Manager 5.4 software. Results A total of 21 studies with 54,276 COVID-19 patients were included in this meta-analysis. This meta-analysis showed that OSA was associated with composite poor outcome [OR 1.72 (95% CI 1.55 – 1.91), p < 0.00001, I 2 = 36%, random-effect modelling] and its subgroup which comprised of severe COVID-19 [OR 1.70 (95% CI 1.18 – 2.45), p = 0.005], ICU admissions [OR 1.76 (95% CI 1.51 – 2.05), p < 0.00001], the need for mechanical ventilation [OR 1.67 (95% CI 1.48 – 1.88), p < 0.00001], and mortality [OR 1.74 (95% CI 1.39 – 2.19), p < 0.00001]. Conclusions Extra care and close monitoring should be provided to patients with OSA to minimize the risk of infections. Simple questionnaires such as STOP-Bang questionnaire can be used for screening patients who may be at risk for severe adverse outcomes.

Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis

“…Finally, obesity results in physiological lung alterations, such as decreased functional residual capacity and hypoxemia [ 67 ]. In addition, obstructive sleep apnoea hypopnea syndrome (OSAHS) increases adverse outcomes of COVID-19 [ 68 ]. The etiology of OSAHS is complex, and obesity is one of the main causes of the syndrome.…”

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression

“…contribute to the development of severe form of Covid-19, causing further inflammation and immune dysfunction that leads to the formation of cytokines storm which is life threatening. [2][3][4][5][6][7] Several therapies had been proposed to control and manage these conditions. [8][9][10][11][12][13][14] Recently the use of GLP1-RA, as one alternative to treat DM patients, had shown promising effect to reduce excessive inflammation-induced acute lung injury and improving Covid-19 outcome.…”

Vitamin D supplementation and Covid‐19 outcomes: A systematic review, meta‐analysis and meta‐regression

“…Individuals with comorbidities such as obesity, diabetes, chronic respiratory disease, cardiovascular disease and other immunocompromising conditions are facing higher risks in developing the severe form of SARS‐CoV‐2 infections. 4 , 5 , 6 , 7 , 8 , 9 For the past months, medical therapies to treat Covid‐19 have been growing and evolving rapidly, ranging from supportive care, antivirals, anti‐inflammatory agents and possible supplementations such as vitamin D. 10 , 11 , 12 , 13 Several studies have shown that vitamin D has antiviral properties and potential roles against acute lung injury or ARDS, making large interest on vitamin D has rapidly emanated even in the early beginning of pandemic. 14 , 15 Low vitamin D serum levels is associated with an increase in inflammatory cytokine levels and significant increase of risk to develop pneumonia and viral respiratory tract infections, which both contribute to the development of ARDS.…”